1/6
08:19 am
syrs
BlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President [Yahoo! Finance]
Low
Report
BlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President [Yahoo! Finance]
12/31
02:50 am
syrs
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
High
Report
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/23
02:12 am
syrs
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/15
02:03 am
syrs
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/7
02:07 am
syrs
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/29
03:10 am
syrs
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/22
12:31 am
syrs
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/14
12:36 pm
syrs
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal [Yahoo! Finance]
Medium
Report
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal [Yahoo! Finance]
11/4
11:14 pm
syrs
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/4
11:00 am
syrs
The Schall Law Firm Invites Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Related Infractions
Low
Report
The Schall Law Firm Invites Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Related Infractions
11/3
11:00 am
syrs
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm
Medium
Report
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm
11/2
11:00 am
syrs
The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
Medium
Report
The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
11/2
10:55 am
syrs
Syros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023) [Yahoo! Finance]
Medium
Report
Syros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023) [Yahoo! Finance]
11/1
08:15 am
syrs
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
High
Report
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
10/31
11:00 am
syrs
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm
Low
Report
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm
10/31
07:30 am
syrs
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update
Low
Report
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update
10/30
11:00 am
syrs
The Schall Law Firm Urges Investor Participation In An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
Low
Report
The Schall Law Firm Urges Investor Participation In An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
10/29
11:00 am
syrs
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders Are Encouraged To Contact The Schall Law Firm
High
Report
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders Are Encouraged To Contact The Schall Law Firm
10/28
11:00 am
syrs
The Schall Law Firm Urges Investor Participation In An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
Low
Report
The Schall Law Firm Urges Investor Participation In An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
10/27
11:00 am
syrs
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm
Low
Report
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm
10/26
11:00 am
syrs
The Schall Law Firm Urges Investor Participation In An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
Low
Report
The Schall Law Firm Urges Investor Participation In An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
10/25
11:00 am
syrs
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm
Low
Report
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm
10/24
11:00 am
syrs
The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
Medium
Report
The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
10/24
07:08 am
syrs
Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
Medium
Report
Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
10/23
11:00 am
syrs
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm
High
Report
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm